Re-engineered psychedelic drug retains therapeutic activity in mice, while limiting negative side effects

A redesigned psychedelic compound retains therapeutic activity while limiting unwanted side-effects during testing on mice. The molecule’s structure was adjusted to avoid interactions with a specific subset of serotonin receptors, potentially offering a blueprint for safer neuropsychiatric drugs.